Emerson Electric (EMR) Stock Analysis

HOLD

EMR Equity Research — HOLD — June 2026

Rating date

Jun 2, 2026

69 days ago

Desk view

HOLD

5D move

-2.08%

Neutral (HOLD unscored)

Peer rank

67p

Investment card · EMR

From June 2025 through early June 2026, EMR traced a steady upward path. The stock opened the window at ~$117 (June 2, 2025) and ground higher through mid-2025, reaching the $130s by August and consolidating in a $124–$132 range through ...

Desk rating

HOLD

Tactical HOLD · 12M OW

Horizon

Tactical HOLD · 12M OVERWEIGHT

Confidence

Medium

Invalidation

Thesis weakens if catalysts slip or risk markers breach stated levels.

Bias

HOLD

Catalysts

  • Bullish long-term trend remains intact — EMR has traded above its rising 200-day SMA for the entire window, and the golden cross (50 > 200 SMA) is firmly established.
  • The May 2026 pullback was sharp but appears corrective — The V-shaped recovery from $130.65 back to $141.65 suggests buyers stepped in aggressively near the $130 support zone.
  • Momentum has flipped from bearish to bullish — RSI recovered from oversold to neutral-bullish (55.9), and the MACD generated a bullish crossover above zero in late May.

Risks

  • Event-driven repricing risk if expectations diverge from incoming evidence.

Market chart

Price context alongside the research narrative.

EMR Research Note

Full desk note for Jun 2, 2026. Use tabs for catalysts, valuation and risks, or open the full note.

29 min read

WebserviceX · Agentic Research Desk

EMR Equity Research Note

Published Jun 2, 2026 · Desk view HOLD · Generated 2026-06-03T05:01:54Z · Maintained by Walter Vijayakumar · Methodology · Track record

EMR Stock Rating Summary

EMR bias

HOLD

Horizon

Tactical HOLD · 12M OVERWEIGHT

EMR key risk

Event-driven repricing risk if expectations diverge from incoming evidence.

EMR catalyst watch

Bullish long-term trend remains intact — EMR has traded above its rising 200-day SMA for the entire window, and the golden cross (50 > 200 SMA) is firmly established.

Invalidation

Thesis weakens if catalysts slip or risk markers breach stated levels.

Confidence

Medium

How the call aged · 5D

-2.08%Neutral (HOLD unscored)Peer 67p
Expand

Grading rule: BUY/OVERWEIGHT scores Correct when forward return > 0; UNDERWEIGHT/SELL when < 0; HOLD is Neutral. Window uses 5 US trading sessions after the rating entry close vs benchmark SPY. Scorecard computed 2026-06-09T07:21:35.967261+00:00.

5D move

-2.08%

2026-06-02 → 2026-06-08

Outcome

Neutral (HOLD unscored)

5D trend

+0.75%

Vol (20D ann.)

+37.86%

vs SPY: -0.44%

Close 142.03 (USD, vendor closes)

Batch scorecard · 2026-06-02 · EMR

Publish QC

passed
Expand

Pipeline fingerprint 781c0b04aa680fac

No QC issues recorded.